Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 214

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials

Fernandes, Gilson C., Fernandes, Amanda, Cardoso, Rhanderson, Penalver, Jorge, Knijnik, Leonardo, Mitrani, Raul D., Myerburg, Robert J., Goldberger, Jeffrey J. · 2021 · Heart Rhythm

Abstract

BACKGROUND Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce hospitalizations and death from heart failure (HF), but their effect on arrhythmia expression has been poorly investigated. OBJECTIVE To evaluate the association of SGLT2i with arrhythmias in patients with type 2 diabetes mellitus (T2DM) or HF. METHODS We searched Pubmed and ClinicalTrials.gov. Two independent investigators identified randomized, double-blind trials that compared SGLT2i with placebo or active control for adults with T2DM or HF. Primary outcomes were incident atrial arrhythmias, ventricular arrhythmias (VA) and sudden cardiac death (SCD). RESULTS We included 34 randomized (25 placebo-controlled and 9 active-controlled) trials with 63,166 patients (35,883 SGLT2i vs 27,273 control - mean age 53-67 years, 63% male). Medications included canagliflozin, dapagliflozin, empagliflozin or ertugliflozin. Except for one study on HF, all patients had T2DM. Follow-up ranged from 24 weeks to 5.7 years. The cumulative incidence of events was low - 3.6, 1.4 and 2.5 per 1,000 patient-years for atrial arrhythmias, VA and SCD, respectively. SGLT2i therapy was associated with a significant reduction in risk of incident atrial arrhythmias (OR, 0.81, 95% CI 0.69-0.95; P=0.008) and the "SCD" component of the SCD outcome (OR, 0.72, 95% CI 0.54-0.97; P=0.03) compared with control. There was no significant difference in incident VA or the "cardiac arrest" SCD component between groups. CONCLUSIONS SGLT2i are associated with significantly reduced risks of incident atrial arrhythmias and SCD in patients with T2DM. Prospective trials are warranted to confirm the antiarrhythmic effect of SGLT2i and whether this is a class or drug-specific effect.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.hrthm.2021.03.028

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 214

Metadata

Authors
Fernandes, G. C., Fernandes, A., Cardoso, R., Penalver, J., Knijnik, L., Mitrani, R. D., Myerburg, R. J., & Goldberger, J. J.
Venue
Heart Rhythm
Publisher
Elsevier BV
Published
2021-07
Volume
18
Issue
7
Pages
1098-1105
ISSN
1547-5271 (ISSN-L)
OpenAlex
W3136045622
Cited by
214
References
8
FWCI
9.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials. https://app.cochat.ai/papers/10.1016/j.hrthm.2021.03.028
The paper
Fernandes, G. C., Fernandes, A., Cardoso, R., Penalver, J., Knijnik, L., Mitrani, R. D., Myerburg, R. J., & Goldberger, J. J. (2021). Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2021.03.028

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.